HEALTHCAP STRENGTHENS SENIOR TEAM
Mårten Steen Promoted to Co-Managing Partner Expanded team with the appointment of … Continue reading “HEALTHCAP STRENGTHENS SENIOR TEAM”
Mårten Steen Promoted to Co-Managing Partner Expanded team with the appointment of … Continue reading “HEALTHCAP STRENGTHENS SENIOR TEAM”
LONDON, 6 October 2021: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), … Continue reading “Arix today announces the following updates to its Board and Executive team”
Industry veteran with decades of experience in company formation, scientific research, and … Continue reading “Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer”
The Hague, Netherlands, 5 October 2021: Amber Implants, an innovative medical technology company … Continue reading “Amber Implants VCFix® spinal system receives US FDA Breakthrough Designation”
DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare For development of … Continue reading “DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare”
Torsten Mummenbrauer, Chief Executive Officer of ExeVir will be speaking on a … Continue reading “ExeVir Bio BV announces its participation in the 8th Annual Healthtech Investment Forum organized by SACHS Associates taking place virtually 5th-6th October 2021.”
Isabel Ferreira speaking on the “Platform Technologies and Novel Therapeutics” Panel Versameb … Continue reading “Versameb at Sachs 21st Annual Biotech in Europe Forum”
OGA inhibitors offer multimodal mechanism of action with potential for multiple approaches … Continue reading “Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences”
• Level 1 evidence from the MAF Test® analyses of the NSABP-B34 … Continue reading “Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura Medical Announces Interim Results for the Six Months ended 30 June 2021”
Partner Shanghai Miracogen (fully owned by LEPU BIOPHARMA CO., LTD) commences US … Continue reading “Third ADC with Synaffix’s Technology Enters Clinical Development”
The project will support more than 4,300 refugees and other conflict-affected populations … Continue reading “The Novo Nordisk Foundation is awarding a grant of DKK 20 million to support an innovative new project aiming to increase sustainable livelihoods for Syrian refugees in Jordan.”
Polθ inhibitor, ART4215, is the first selective, orally bioavailable, small molecule inhibitor of … Continue reading “Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215”
Three abstracts accepted at EBJIS Annual Meeting demonstrating efficacy of STIMULAN beads … Continue reading “Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting”
Brighton, United Kingdom – 27 September 2021 – Destiny Pharma (AIM: DEST), a … Continue reading “Destiny Pharma plc: Expansion of clinical pipeline”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura Medical Announces Collaboration with Labatec Pharma to Commercialise MED3000 in the Gulf and Middle East Region”
Hangzhou, China and Diepenbeek, Belgium, (August 18, 2021): Worg Pharmaceuticals (Hangzhou) Co., Ltd … Continue reading “Worg Pharma to Acquire Apitope”
September 22nd 2021: EXACT Therapeutics AS (‘EXACT-Tx’) announces its interim results for … Continue reading “EXACT Therapeutics AS announces interim results for first half 2021”
BioInnovation Institute (BII), an international commercial foundation with a non-profit objective of … Continue reading “BII welcomes four new companies to the Creation House program”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
